{"id":58566,"date":"2023-12-12T07:05:25","date_gmt":"2023-12-12T06:05:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/"},"modified":"2023-12-12T07:05:25","modified_gmt":"2023-12-12T06:05:25","slug":"meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/","title":{"rendered":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal"},"content":{"rendered":"<div>\n<p>KNOXVILLE, Tenn.&#8211;(BUSINESS WIRE)&#8211;Meilleur Technologies, Inc. today announced a research collaboration agreement with the Young Blood Institute (YBI) on the use of Meilleur\u2019s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status of amyloid plaque in the brain. Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s Disease (AD).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/5\/MTI_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/5\/MTI_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/22\/MTI_logo.jpg\"><\/a><\/p>\n<p>\nThe collaboration is focused on using [F-18]NAV-4694 as an imaging biomarker in the YBI Am\u03b2ARI (Amyloid \u03b2eta Assessment &amp; Removal Intervention) study. The Young Blood Institute will utilize Meilleur\u2019s [F-18]NAV-4694 tracer to aid YBI\u2019s study of early detection and clearance of Amyloid \u03b2eta to prevent Alzheimer\u2019s disease using Therapeutic Plasma Exchange. Colin Masters, MD, Professor of Dementia Research at the Florey Institute and the University of Melbourne, Melbourne, Australia, will lead the study as YBI Principal Investigator.<\/p>\n<p>\nAccording to Dr. Masters, \u201cThere are multiple tracers for PET scanning available at the moment, and I insisted that we get the scientifically preferred tracer for this clinical study so that the trials we\u2019re planning will provide the strongest clinical evidence of how significantly plasma exchange shifts the PET signal. <sup>ref<\/sup>\u201d<\/p>\n<p>\nMark Urdahl, President &amp; CEO of the Young Blood Institute, added, \u201cWhile we plan to use the latest mass spec A\u03b2 blood tests to screen subjects for potential Amyloid \u03b2eta accumulations in the brain, PET scanning remains the primary modality for confirmation of diagnosis. And NAV4694 provides the highest signal strength of any of the F-18 tracers<sup> ref<\/sup>.\u201d<\/p>\n<p>\n\u201cMeilleur is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative diseases,\u201d said Rick Hiatt, Chief Ex\u00e9cutive Officier, Meilleur Technologies, Inc. \u201cWe believe NAV4694 has unique properties that will prove useful in developing current and future therapeutic agents in neurodegenerative disease and are excited to add YBI to our growing network of pharmaceutical and academic partners, leveraging our globally validated production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.\u201d<\/p>\n<p>\n<b>Ref. : Pascoal et al. 2020. PiB: Klunk et al., Alzheimer Dement, 2015. NAV: Rowe et al., J Nucl Med, 2016. FBB: Rowe et al., EJNMMI, 2017. FBP: Navitsky et al., Alzheimer Dement, 2018. FLT: Battle et al., EJNMMI Research, 2018.<\/b><\/p>\n<p>\n<b>About Meilleur Technologies, Inc.<\/b><\/p>\n<p>\nMeilleur\u2019s vision is to be the premier provider of imaging biomarkers for neurological pathologies, associated information technology and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. Meilleur\u2019s late-stage biomarker, NAV-4694, provides Pharma and Academic researchers with a \u2018best in class\u2019 second generation \u00df-Amyloid imaging biomarker capable of detecting and validating Disease Modifying Therapies with the highest possible precision and accuracy for determining the risk of Alzheimer\u2019s disease.<\/p>\n<p>\n<b>About the Young Blood Institute<\/b><\/p>\n<p>\nThe Young Blood Institute was established as a non-profit clinical research organization to study new uses for Therapeutic Plasma Exchange therapies that have been used for decades to address autoimmune disorders. YBI\u2019s study focus on age-associated disorders, as well as early pre-clinical findings and unique protocol developments for cognitively normal subjects, have led to an expansion into secondary prevention studies and strategies around dementia and dementia of the Alzheimer\u2019s type, in particular.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMeilleur Technologies, Inc.<br \/>\n<br \/>Rick Hiatt, 617-906-2715<\/p>\n<p>Young Blood Institute<br \/>\n<br \/>Mark Urdahl, 844-924-4648<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>KNOXVILLE, Tenn.&#8211;(BUSINESS WIRE)&#8211;Meilleur Technologies, Inc. today announced a research collaboration agreement with the Young Blood Institute (YBI) on the use of Meilleur\u2019s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status of amyloid plaque in the brain. Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s Disease &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58566","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am\u03b2ari-study-on-amyloid-removal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"KNOXVILLE, Tenn.&#8211;(BUSINESS WIRE)&#8211;Meilleur Technologies, Inc. today announced a research collaboration agreement with the Young Blood Institute (YBI) on the use of Meilleur\u2019s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status of amyloid plaque in the brain. Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s Disease ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am\u03b2ari-study-on-amyloid-removal\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-12T06:05:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal\",\"datePublished\":\"2023-12-12T06:05:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/\"},\"wordCount\":579,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231211787081\\\/en\\\/1966913\\\/21\\\/MTI_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/\",\"name\":\"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231211787081\\\/en\\\/1966913\\\/21\\\/MTI_logo.jpg\",\"datePublished\":\"2023-12-12T06:05:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231211787081\\\/en\\\/1966913\\\/21\\\/MTI_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231211787081\\\/en\\\/1966913\\\/21\\\/MTI_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am\u03b2ari-study-on-amyloid-removal\/","og_locale":"en_US","og_type":"article","og_title":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend","og_description":"KNOXVILLE, Tenn.&#8211;(BUSINESS WIRE)&#8211;Meilleur Technologies, Inc. today announced a research collaboration agreement with the Young Blood Institute (YBI) on the use of Meilleur\u2019s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status of amyloid plaque in the brain. Amyloid plaques are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s Disease ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am\u03b2ari-study-on-amyloid-removal\/","og_site_name":"Pharma Trend","article_published_time":"2023-12-12T06:05:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal","datePublished":"2023-12-12T06:05:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/"},"wordCount":579,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/","url":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/","name":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg","datePublished":"2023-12-12T06:05:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231211787081\/en\/1966913\/21\/MTI_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/meilleur-technologies-inc-announces-use-of-the-next-generation-amyloid-pet-imaging-biomarker-nav-4694-in-the-young-blood-institutes-am%ce%b2ari-study-on-amyloid-removal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute\u2019s Am\u03b2ARI study on Amyloid Removal"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58566"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58566\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}